AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20167278 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 40 mg/kg/day (arm B)
Number of subjects: 149
Study 20167278 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 149
Study 18025879 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV at week 0 and PPV at week 4 (n = 106)
Number of subjects: 212
Study 18025879 — intervention group
Group type: COMPARATOR
Intervention: PPV alone at week 4 (n = 106)
Number of subjects: 212
Study 16220212 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified time budget measure of activity levels
Number of subjects: 42
Study 16220212 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Functioning Scale (SFS)
Number of subjects: 42
Study 12113383 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary intervention for underweight patients (UW group)
Number of subjects: 87
Study 12113383 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary intervention for overweight patients (OW group)
Number of subjects: 87
Study 12113383 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary intervention for normal weight patients (NW group)
Number of subjects: 87
Study 12113383 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 87
Study 10029805 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli asparaginase
Number of subjects: 251
Study 10029805 — intervention group
Group type: EXPERIMENTAL
Intervention: Erwinia chrysanthemi asparaginase
Number of subjects: 251
Study 10029805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Number of subjects: 251
Study 10029805 — intervention group
Group type: COMPARATOR
Intervention: In vitro nonresponders to asparaginase
Number of subjects: 251
Study 7560366 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcavity restorations
Number of subjects: 28
Study 7560366 — intervention group
Group type: COMPARATOR
Intervention: Modified Black's Class II cavity restorations
Number of subjects: 28
Study 2328959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (10% solution in 5% dextrose in water)
Number of subjects: 15
Study 2328959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water alone)
Number of subjects: 15
Study 7016402 — intervention group
Group type: EXPERIMENTAL
Intervention: L-valine (600 mumol/min)
Number of subjects: 4
Study 7016402 — intervention group
Group type: EXPERIMENTAL
Intervention: L-isoleucine (150 mumol/min)
Number of subjects: 4
Study 7016402 — intervention group
Group type: EXPERIMENTAL
Intervention: L-leucine (300 mumol/min)
Number of subjects: 4
Study 7016402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of branched-chain amino acids (70% L-leucine, 20% L-valine, 10% L-isoleucine; 270 mumol/min)
Number of subjects: 4
Study 31837722 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power Universal
Number of subjects: 1030
Study 31837722 — intervention group
Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 1030
Study 28393350 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated social communication intervention (12 sessions delivered between 9 and 14 months of age)
Number of subjects: 54
Study 28393350 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated social communication intervention
Number of subjects: 54
Study 28393350 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study 26526317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 91
Study 26526317 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 91
Study 23887247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (PE'CO2 ≈ 50 mm Hg)
Number of subjects: 1215
Study 23887247 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (PE'CO2 ≈ 35 mm Hg)
Number of subjects: 1215
Study 20940355 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeic acid phenethyl esther
Number of subjects: 0
Study 20940355 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride
Number of subjects: 0
Study 20940355 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride + caffeic acid phenethyl esther
Number of subjects: 0
Study 20940355 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 19016732 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation therapy
Number of subjects: 21
Study 19016732 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 21
Study 18059399 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of meat, total dietary iron, iron from meat, haem iron, and non-haem iron
Number of subjects: 34148
Study 16267908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy and local-regional radiotherapy
Number of subjects: 0
Study 16267908 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11867243 — intervention group
Group type: EXPERIMENTAL
Intervention: CASC at 2 weeks (T(2W))
Number of subjects: 110
Study 11867243 — intervention group
Group type: EXPERIMENTAL
Intervention: CASC at 3 months (T(3M))
Number of subjects: 110
Study 10526275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with cisplatin plus etoposide (n = 12)
Number of subjects: 30
Study 10526275 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy with cisplatin plus etoposide (n = 18)
Number of subjects: 30
Study 10526275 — intervention group
Group type: COMPARATOR
Intervention: (201)Tl retention
Number of subjects: 30
Study 7476341 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 35
Study 7476341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight loss intervention)
Number of subjects: 35
Study 2301856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm nitrogen dioxide (NO2)
Number of subjects: 9
Study 2301856 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 9
Study 7034196 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (DFS) 1g
Number of subjects: 15
Study 7034196 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 4g
Number of subjects: 15
Study 7034196 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (DFS)
Number of subjects: 15
Study 7034196 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 15
Study 29660295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexclusive breastfeeding
Number of subjects: 128
Study 29660295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of support during the lactation period
Number of subjects: 128
Study 29660295 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty breastfeeding
Number of subjects: 128
Study 29660295 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration shorter than 12 months in a previous pregnancy
Number of subjects: 128
Study 29660295 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants' birth weight less than 2,300 g
Number of subjects: 128
Study 25537365 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH (100 mCi)
Number of subjects: 121
Study 25537365 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH (70 mCi)
Number of subjects: 121
Study 25537365 — intervention group
Group type: COMPARATOR
Intervention: LT4 withdrawal (100 mCi)
Number of subjects: 121
Study 25537365 — intervention group
Group type: COMPARATOR
Intervention: LT4 withdrawal (70 mCi)
Number of subjects: 121
Study 25539648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF‐FTC)
Number of subjects: 0
Study 25539648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21738093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortoss
Number of subjects: 256
Study 21738093 — intervention group
Group type: COMPARATOR
Intervention: PMMA
Number of subjects: 256
Study 20593942 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of cervical cancer
Number of subjects: 205
Study 20593942 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of HPV virus as a risk factor
Number of subjects: 205
Study 20593942 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of multiple sexual partners as a risk factor
Number of subjects: 205
Study 20593942 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use among those aware of cervical cancer
Number of subjects: 205
Study 20593942 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of Pap smear test
Number of subjects: 205
Study 20593942 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Pap smear for cervical cancer detection
Number of subjects: 205
Study 19005973 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 2411
Study 19005973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea consumption
Number of subjects: 2411
Study 19005973 — intervention group
Group type: COMPARATOR
Intervention: Dietary fiber
Number of subjects: 2411
Study 17162998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 600
Study 17162998 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 600
Study 12514410 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 200 mg once daily
Number of subjects: 420
Study 12514410 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 420
Study 12514410 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 500 mg once daily
Number of subjects: 420
Study 12514410 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir 750 mg three times daily
Number of subjects: 420
Study 10378564 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with small volume spacer (5 puffs, 450 microg albuterol)
Number of subjects: 30
Study 10378564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (2.5 mg albuterol)
Number of subjects: 30
Study 10378564 — intervention group
Group type: COMPARATOR
Intervention: MDI port on right-angle adaptor (5 puffs, 450 microg albuterol)
Number of subjects: 30
Study 8686821 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 0
Study 8686821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg.kg‐1 with atropine 0.02 mg.kg‐1
Number of subjects: 0
Study 1760834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 40
Study 7471605 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 0 mg (10/0)
Number of subjects: 65
Study 7471605 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 10 mg (10/10)
Number of subjects: 65
Study 7471605 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 20 mg (10/20)
Number of subjects: 65
Study 7471605 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 40 mg (10/40)
Number of subjects: 65
Study 7471605 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 80 mg (10/80)
Number of subjects: 65
Study 7471605 — intervention group
Group type: COMPARATOR
Intervention: Ticrynafen (T) 250 mg daily
Number of subjects: 65
Study 7471605 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 50 mg daily
Number of subjects: 65
Study 31412818 — intervention group
Group type: EXPERIMENTAL
Intervention: Action 3:30R teaching assistant-led after-school intervention
Number of subjects: 0
Study 31412818 — intervention group
Group type: EXPERIMENTAL
Intervention: Action 3:30R TA training
Number of subjects: 0
Study 31412818 — intervention group
Group type: EXPERIMENTAL
Intervention: Action 3:30R intervention
Number of subjects: 0
Study 31412818 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 0
Study 27610553 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application providing real-time feedback during resistance training
Number of subjects: 42
Study 26860492 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasound therapy for 6 minutes at 1.5 Watt/cm2 dose with 1 MHz frequency for 15 days
Number of subjects: 59
Study 26860492 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound therapy
Number of subjects: 59
Study 23320967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoetin (500 U/kg, 2 doses, 24 hours apart)
Number of subjects: 160
Study 23320967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21249383 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensor board (MSB)
Number of subjects: 57
Study 19353740 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio 025 600 mg/day + PEG IFN-alpha2a 180 microg/week
Number of subjects: 0
Study 19353740 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio 025 1000 mg/day + PEG IFN-alpha2a 180 microg/week
Number of subjects: 0
Study 19353740 — intervention group
Group type: COMPARATOR
Intervention: Debio 025 1000 mg/day (monotherapy)
Number of subjects: 0
Study 19353740 — intervention group
Group type: COMPARATOR
Intervention: PEG IFN-alpha2a 180 microg/week (monotherapy)
Number of subjects: 0
Study 17868953 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat flavored cream cheese (orange or banana)
Number of subjects: 24
Study 17868953 — intervention group
Group type: COMPARATOR
Intervention: Low fat flavored cream cheese (orange or banana)
Number of subjects: 24
Study 15497297 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted injection system (Wand Plus)
Number of subjects: 40
Study 15497297 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe technique
Number of subjects: 40
Study 11556573 — intervention group
Group type: EXPERIMENTAL
Intervention: HA1 (500 mg three times daily for 3 days, total dose: 4,500 mg)
Number of subjects: 120
Study 11556573 — intervention group
Group type: EXPERIMENTAL
Intervention: HA2 (500 mg three times daily for the first and the third day, total dose: 3,000 mg)
Number of subjects: 120
Study 11556573 — intervention group
Group type: EXPERIMENTAL
Intervention: HA3 (500 mg three times for one day followed by 500 mg once daily for 7 days, total dose: 4,500 mg)
Number of subjects: 120
Study 9577350 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 1200 micrograms buccal spray
Number of subjects: 8
Study 9577350 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 8
Study 7909450 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 28
Study 2905188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5‐fluorouracil (FU) and 1‐(2‐chloroethyl)‐3‐(4‐methylcyclohexil)‐1‐nitrosourea (Me‐CCNU) after surgery
Number of subjects: 235
Study 2905188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo‐immunotherapy (FU, Me‐CCNU and levamisole) after surgery
Number of subjects: 235
Study 2905188 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 235
Study 30753662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus OH4L (Oral Health 4 Life)
Number of subjects: 718
Study 30942789 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries
Number of subjects: 23
Study 30942789 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fries
Number of subjects: 23
Study 30942789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hash browns
Number of subjects: 23
Study 30942789 — intervention group
Group type: COMPARATOR
Intervention: Whole wheat pancake
Number of subjects: 23
Study 29767924 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the model of health beliefs (four training sessions in three months)
Number of subjects: 90
Study 29767924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 90
Study 26057204 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (PER)
Number of subjects: 0
Study 26057204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 23782457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Number of subjects: 20127
Study 23782457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 20127
Study 23782457 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20127
Study 22275710 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative viscosity training
Number of subjects: 30
Study 22275710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined field training (augmented inertia with negative viscosity)
Number of subjects: 30
Study 22275710 — intervention group
Group type: COMPARATOR
Intervention: Null force field (control)
Number of subjects: 30
Study 19781320 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 167
Study 19781320 — intervention group
Group type: COMPARATOR
Intervention: Manual suture
Number of subjects: 167
Study 16309958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 107
Study 16309958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 107
Study 16309958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 107
Study 16309958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 32 mg
Number of subjects: 107
Study 16309958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 15509406 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-booklet questionnaire
Number of subjects: 3836
Study 15509406 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sided questionnaire
Number of subjects: 3836
Study 15509406 — intervention group
Group type: COMPARATOR
Intervention: Double-sided questionnaire
Number of subjects: 3836
Study 15509406 — intervention group
Group type: COMPARATOR
Intervention: Multiple-booklet questionnaire
Number of subjects: 3836
Study 11913275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide in-office whitening system for 30 minutes
Number of subjects: 24
Study 11913275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide in-office whitening system for 45 minutes
Number of subjects: 24
Study 11913275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide in-office whitening system for 60 minutes
Number of subjects: 24
Study 11913275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 15% hydrogen peroxide in-office treatment and 10% carbamide peroxide take-home treatment
Number of subjects: 24
Study 9393426 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra-System implants (HA-coated cylinders)
Number of subjects: 2633
Study 9393426 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra-System implants (titanium alloy baskets)
Number of subjects: 2633
Study 9393426 — intervention group
Group type: COMPARATOR
Intervention: Bone quality 1 (BQ-1)
Number of subjects: 2633
Study 9393426 — intervention group
Group type: COMPARATOR
Intervention: Bone quality 2 (BQ-2)
Number of subjects: 2633
Study 9393426 — intervention group
Group type: COMPARATOR
Intervention: Bone quality 3 (BQ-3)
Number of subjects: 2633
Study 9393426 — intervention group
Group type: COMPARATOR
Intervention: Bone quality 4 (BQ-4)
Number of subjects: 2633
Study 9393426 — intervention group
Group type: COMPARATOR
Intervention: Clinical centers
Number of subjects: 2633
Study 8200890 — intervention group
Group type: EXPERIMENTAL
Intervention: Single plate fixation with bone cement
Number of subjects: 24
Study 8200890 — intervention group
Group type: EXPERIMENTAL
Intervention: Double plating with bone cement
Number of subjects: 24
Study 8200890 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush rods with bone cement
Number of subjects: 24
Study 8200890 — intervention group
Group type: COMPARATOR
Intervention: Intact humeri
Number of subjects: 24
Study 8200890 — intervention group
Group type: COMPARATOR
Intervention: Matched humeri with a defect
Number of subjects: 24
Study 3295096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 46
Study 3295096 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 46
Study 3295096 — intervention group
Group type: COMPARATOR
Intervention: Both Ioxaglate and Iopamidol
Number of subjects: 46
Study 3295096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac patients
Number of subjects: 46
Study 3295096 — intervention group
Group type: COMPARATOR
Intervention: Non-cardiac patients
Number of subjects: 46
Study 3295096 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 46
Study 29329181 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting at 8 weeks
Number of subjects: 2253
Study 29329181 — intervention group
Group type: COMPARATOR
Intervention: Retesting at 16 weeks
Number of subjects: 2253
Study 29329181 — intervention group
Group type: COMPARATOR
Intervention: Retesting at 26 weeks
Number of subjects: 2253
Study 29329181 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (8, 16, 26 weeks)
Number of subjects: 2253
Study 26521660 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized educational booklet and take-home educational materials
Number of subjects: 14
Study 26521660 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials (control)
Number of subjects: 14
Study 25428762 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 8 weeks
Number of subjects: 90
Study 25428762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25428762 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 90
Study 23442031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 51
Study 23442031 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 20580422 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg injected once weekly
Number of subjects: 491
Study 20580422 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg oral once daily
Number of subjects: 491